LONDON (Reuters) -Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal. Last ...

BioNTech co-founders Dr. Ugur Sahin and Dr. Ozlem Tureci in its headquarters in Germany on Jan. 3.Photograph by Dina Litovsky—Redux for TIME “No!” The doctor snapped. “Look at me!” I had been staring ...

US pharmaceutical giant Pfizer and German firm BioNTech lost Friday a court appeal in the latest step of a multi-million pound battle against US rival Moderna over the COVID-19 vaccine. The Appeals ...

The race to greenlight a COVID-19 vaccine in the United States has entered its final sprint, with one leading candidate becoming the first to release preliminary results showing its vaccine is more ...

Last year, the High Court ruled that one of Moderna’s patents relating to the messenger RNA (mRNA) technology, which underpinned its COVID-19 vaccine, was valid and that Pfizer and BioNTech’s ...

Pfizer is selling its remaining stake in COVID-19 vaccine partner BioNTech. The U.S. drugmaker is offering about 4.55 million American depositary receipts in an overnight block trade, marketed at ...

Pfizer has axed 11 programs including two pipeline assets from its $43 billion Seagen acquisition, work on a BioNTech-partnered mRNA vaccine and a midstage metabolic dysfunction-associated ...

Pfizer's Canadian unit and BioNTech said they have received approval in Canada for their updated Comirnaty Covid-19 vaccine. The companies said Monday the updated vaccine targets the Omicron LP.8.1 ...